Betagenon and AstraZeneca sign collaboration agreement on therapies for type 2 diabetes
BETAGENON AND ASTRAZENECA SIGN COLLABORATION AGREEMENT ON THERAPIES FOR TYPE 2 DIABETES Stockholm, Sweden, October 24, 2003 - Betagenon AB a Swedish biotechnology company focused on the discovery and early stage development of drug therapies for treatment of type 2 diabetes announced today that it has entered into a collaboration agreement with AstraZeneca. Type 2 diabetes is the most common metabolic disease with a high incidence in Western countries. Approximately 150 million people are currently affected by the disease and it is regarded to be epidemic in USA. Today's most widely used